Interaction between somatic mutations and germline variants contributes to clinical heterogeneity in cancer

Abstract

Deciphering principles of inter-tumoral heterogeneity is crucial for refinement of precision oncology. We have recently demonstrated that ‘oncogenic cooperation‘ between somatic mutations and regulatory germline variants can serve as a major cause for inter-tumoral heterogeneity, suggesting the requirement of integrating the regulatory genome into ‘omics‘-based precision oncology.

Keywords

• oncogenic cooperation
• ewing sarcoma
• mybl2
• b-myb
• cancer
• cdk2 inhibitors
• ewsr1-fli1
• clinical outcome
• predictive biomarker